试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-30
Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers
编号:NCT00882193登记状态:提前终止企业 / 申办者:University of Nebraska
药物 / 成分:Betaine、Peginterferon alpha 2a、Ribavirin
登记的停止原因(原文):new medications with improved response released
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-30
Preemptive Therapy of GVHD
编号:NCT01994824登记状态:提前终止企业 / 申办者:University of Calgary
药物 / 成分:rabbit antithymocyte globulin
登记的停止原因(原文):The trend was observed toward higher mortality among the patients receiving the intervention Thymoglobulin on day 8 after hematopoietic cell transplantation.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-30
Edwards Cardioband System ACTIVE Pivotal Clinical Trial (ACTIVE)
编号:NCT03016975登记状态:提前终止企业 / 申办者:Edwards Lifesciences
药物 / 成分:Edwards Cardioband System、Guideline Directed Medical Therapy
登记的停止原因(原文):Procedure and device development
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-30
Synaptic Plasticity and Cognitive Function in RASopathies
编号:NCT03504501登记状态:提前终止企业 / 申办者:Technical University of Munich
药物 / 成分:Lovastatin、Lamotrigine
登记的停止原因(原文):The study has been terminated prematurely due to recruitment difficulties. Current status: recruitment stopped and cleaning of the database is ongoing.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-30
Treatment of Strongyloides Infection
编号:NCT03605758登记状态:提前终止企业 / 申办者:Albert Einstein College of Medicine
药物 / 成分:Ivermectin
登记的停止原因(原文):The original study PI passed away. Primary and Study Completion dates revised to reflect last participant examination date.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-30
Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects
编号:NCT03818672登记状态:提前终止企业 / 申办者:Bausch Health Americas, Inc.
药物 / 成分:Rifaximin
登记的停止原因(原文):Study determined to be infeasible.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-30
Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3
编号:NCT03819660登记状态:提前终止企业 / 申办者:Catalyst Pharmaceuticals, Inc.
药物 / 成分:Amifampridine Phosphate 10 MG Oral Tablet
登记的停止原因(原文):Development of indication not being pursued
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-30
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
编号:NCT03861403登记状态:提前终止企业 / 申办者:Leap Therapeutics, Inc.
药物 / 成分:TRX518、Cyclophosphamide、Avelumab
登记的停止原因(原文):Product development discontinued unrelated to safety.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-30
Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)
编号:NCT03970837登记状态:提前终止企业 / 申办者:GlaxoSmithKline
药物 / 成分:GSK3196165 (Otilimab)、Tofacitinib、Placebo
登记的停止原因(原文):Only Asia cohort is early terminated.Limited efficacy demonstrated in the contRAst program does not support a suitable benefit/risk profile for otilimab as a potential treatment for RA. GSK has decided not to progress with regulatory submissions.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-30
Mandibular Furcation II Regeneration
编号:NCT04059445登记状态:提前终止企业 / 申办者:University of Oslo
药物 / 成分:Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane)、Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain)
登记的停止原因(原文):Recruitment problem
查看官方原始记录 ↗